Long-Term Effects of Cannabis Use?

Long-term cannabis use can affect dependence risk, respiratory health, mental health, and cognition. The risks vary with frequency, age at first use, product strength, route of use, and other health conditions. Evidence is stronger for some outcomes than others: an association in a population study is not proof that cannabis caused a particular person’s illness.

It is also useful to separate repeated intoxication from lasting effects after stopping. A person who uses frequently may experience recurring impairment without every measured change being permanent. Conversely, feeling accustomed to cannabis does not establish that continued use is harmless.

Cannabis Use Disorder, Tolerance, and Withdrawal

The CDC estimates that approximately three in ten people who use cannabis have cannabis use disorder. This is not a prediction that three in ten people who try it once will become addicted. Risk is higher with earlier initiation and more frequent use, and the disorder can range in severity.

Warning signs include unsuccessful attempts to cut down, using more than intended, cravings, and continuing despite problems with health, relationships, or responsibilities. Tolerance means needing more to obtain the same effect; it should prompt a review of use rather than automatic dose escalation.

Cutting down or stopping after regular use can produce withdrawal symptoms such as irritability, anxiety, disturbed sleep, unusual dreams, and reduced appetite. These symptoms can complicate a quit attempt. A clinician or substance-use service can help assess the problem and arrange support.

Lungs: Smoke Exposure Matters

Cannabis smoke contains many of the same irritants, toxins, and carcinogens as tobacco smoke. Regular smoking is associated with cough, mucus production, and bronchitis symptoms. These symptoms generally improve after quitting smoking cannabis.

The evidence does not establish that cannabis has the same lung-cancer or COPD risk as tobacco; CDC identifies those as areas needing more research. That uncertainty does not make smoke safe. Bongs and other smoking devices still expose the lungs to smoke.

Edibles avoid combustion exposure, but do not remove THC-related impairment or dependence risk. They can also take longer to have an effect, increasing the chance of consuming too much. Vaping has its own risks, including reported lung injuries, and should not be described as harmless.

Heart and Blood Vessels

A 2025 systematic review of 24 observational studies found associations between cannabis use and acute coronary syndrome, stroke, and cardiovascular death. The pooled relative-risk estimates were 1.29, 1.20, and 2.10, respectively.

These are relative estimates, not the percentage of users who will have an event. Most included studies were cross-sectional, and differences in exposure measurement, tobacco use, and other factors limit causal interpretation. The findings justify taking cardiovascular risk seriously, but cannot provide a precise personal risk estimate for a particular product or dose.

Mental Health and Cognitive Function

The CDC reports an association with psychosis and schizophrenia, stronger among people who start younger and use more frequently. Cannabis can also trigger anxiety, paranoia, or disorientation. Associations with depression and suicidal thoughts do not mean every case is caused by cannabis, but symptoms that emerge or worsen during use deserve assessment.

Recent cannabis use can impair attention, memory, coordination, and decision-making. Developing brains are especially vulnerable. Longer-term studies suggest possible persistent effects, but genetics, environment, other substance use, and recent intoxication can complicate interpretation. Neither universal permanent damage nor guaranteed full recovery is supported by those uncertainties.

Temporary relief of anxiety or poor sleep is not proof of an effective long-term treatment. Our reviews of anxiety and depression and PTSD distinguish condition-specific research from general claims about cannabis.

Recurrent Vomiting and CBD Liver Effects

Frequent, prolonged cannabis use can be associated with cannabinoid hyperemesis syndrome: recurring episodes of severe nausea, vomiting, and abdominal pain. Sustained cannabis cessation is central to recovery. Repeated vomiting needs medical assessment, both for dehydration and to rule out other causes; changing brands is not an established solution.

CBD also has safety concerns despite lacking the typical THC high. In a 2025 FDA-led randomized trial, healthy adults took CBD at 5 mg/kg per day for 28 days. Liver enzyme elevations above three times the upper limit of normal occurred in 5.6% of CBD recipients and none receiving placebo.

The affected participants had no related clinical symptoms, and enzymes normalized within one to two weeks after stopping. This short study does not measure decades of risk or establish safety at lower doses. It shows why regular CBD use should be included in a medication and liver-health review.

Weight and Immune-System Claims Need Caution

Lower average body weight among cannabis users does not establish a weight-loss benefit. A 2024 CARDIA analysis covering 30 years found lower BMI with current use, but no association with cumulative use and no meaningful BMI change after cessation. The authors considered residual confounding a likely explanation.

Laboratory descriptions of anti-inflammatory or immune-modulating activity likewise do not establish that long-term cannabis use strengthens immunity or treats an inflammatory disease. Clinical benefit must be demonstrated for a particular condition and preparation; our inflammation review examines that distinction.

Reducing Risk and Reviewing Ongoing Use

Canada’s lower-risk guidance recommends avoiding daily or near-daily use and high-potency products, and avoiding driving while impaired. Lower THC exposure can reduce some risks, but does not make a product risk-free. Avoid cannabis during pregnancy and breastfeeding.

If cannabis is part of medical care, review the target symptom, actual benefit, dose changes, adverse effects, and other medicines with the prescriber. A specific therapeutic benefit does not establish general protection from chronic disease, and continued use should have a clear, periodically reassessed purpose.